Science Explorer Interactive view Map
Company · Lebanon · United States

Woomera Therapeutics

woomeratherapeutics.comROR OpenAlex
Research works
18
▲ 178% vs 2013–17
Citations
339
18.7 per fractional work
Top-10% rate
58.6%
record average 16.5%
Open access
58%
world 28%

Not ranked overall: Woomera Therapeutics is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 5.55× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 14.10× its world share, 2 worksImmunology and Micro…Neuroscience: 1.53× its world share, 0 worksNeuroscienceChemistry: 3.44× its world share, 1 worksChemistryHealth Professions: 0.94× its world share, 0 worksHealth ProfessionsMedicine: 2.38× its world share, 6 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 14.1×. Every wedge is a field page.

Which research topics does Woomera Therapeutics publish most on?

By volume in 2022–2025: Protein Degradation and Inhibitors, Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies and Asthma and respiratory diseases.

Protein Degradation and Inhibitors: 1 fractional worksCancer-related Molecular Pathways: 1 fractional worksAdvanced Breast Cancer T…1Advanced Breast Cancer Therapies: 1 fractional worksAsthma and respiratory d…1Asthma and respiratory diseases: 1 fractional worksImmune Cell Function and Interaction: 1 fractional worksPeptidase Inhibition and Analysis: 1 fractional worksRNA Interference and Gen…0RNA Interference and Gene Delivery: 0 fractional worksUbiquitin and proteasome pathways: 0 fractional worksIL-33, ST2, and ILC Pathways: 0 fractional worksClick Chemistry and Applications: 0 fractional works
Molecular BiologyOncologyPulmonary and Respiratory MedicinePhysiology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Protein Degradation and Inhibitors Molecular Biology 1 works
  2. 2 Cancer-related Molecular Pathways Oncology 1 works
  3. 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  4. 4 Asthma and respiratory diseases Physiology 1 works
  5. 5 Immune Cell Function and Interaction Immunology 1 works
  6. 6 Peptidase Inhibition and Analysis Oncology 1 works
  7. 7 RNA Interference and Gene Delivery Molecular Biology 0 works
  8. 8 Ubiquitin and proteasome pathways Molecular Biology 0 works
  9. 9 IL-33, ST2, and ILC Pathways Immunology 0 works
  10. 10 Click Chemistry and Applications Organic Chemistry 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available58.1%not open41.9%

World: 28% of research is openly available.

with international co-authors8.2%domestic only91.8%

World: 19% is written across borders.

How has Woomera Therapeutics's research output changed?

Output in 2018–2022 was 178% higher than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Lebanon

All research institutions in Lebanon

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.